Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (101-110 of 101) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 101 results.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 11

Showing results (101-110 of 101) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 101 results.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 11